Leerink Partnrs Has Bullish Forecast for AMLX Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for Amylyx Pharmaceuticals, now predicting a loss of ($0.45) compared to a previous forecast of ($0.47).
• Multiple brokerages have recently upgraded their ratings on Amylyx Pharmaceuticals, with Goldman Sachs increasing the price target from $10.00 to $20.00 and issuing a "buy" rating.
• As of now, institutional investors and hedge funds own approximately 95.84% of Amylyx Pharmaceuticals’ stock, highlighting significant interest from large investors.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Stock analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a research report issued to clients and investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.45) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals' Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.70) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at $0.50 EPS.

Several other brokerages have also recently weighed in on AMLX. Citigroup began coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 17th. They issued a "buy" rating and a $12.00 price objective for the company. The Goldman Sachs Group boosted their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, September 16th. Bank of America boosted their price target on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, October 3rd. UBS Group raised Amylyx Pharmaceuticals to a "hold" rating in a report on Tuesday, June 24th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Amylyx Pharmaceuticals in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $14.75.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ AMLX opened at $13.48 on Thursday. The stock has a market capitalization of $1.20 billion, a PE ratio of -5.39 and a beta of -0.33. The business has a fifty day moving average price of $10.61 and a two-hundred day moving average price of $7.20. Amylyx Pharmaceuticals has a fifty-two week low of $2.60 and a fifty-two week high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.02).

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $28,000. Valeo Financial Advisors LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter valued at about $35,000. R Squared Ltd grew its position in shares of Amylyx Pharmaceuticals by 99.9% in the 1st quarter. R Squared Ltd now owns 12,736 shares of the company's stock valued at $45,000 after buying an additional 6,366 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $45,000. Finally, BNP Paribas Financial Markets grew its position in shares of Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after buying an additional 5,904 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 29,975 shares of the company's stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $14.38, for a total value of $431,040.50. Following the completion of the transaction, the chief executive officer owned 3,325,301 shares of the company's stock, valued at $47,817,828.38. This represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Frates sold 10,558 shares of the company's stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $14.65, for a total value of $154,674.70. Following the completion of the transaction, the chief financial officer directly owned 280,430 shares of the company's stock, valued at approximately $4,108,299.50. The trade was a 3.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,333 shares of company stock worth $1,319,495. Company insiders own 12.30% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.